

CHAMPIONS ONCOLOGY, INC.  
 Form 4  
 March 23, 2015

**FORM 4**

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
 Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0287  
 Expires: January 31, 2015  
 Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
 Morris Ronnie

2. Issuer Name and Ticker or Trading Symbol  
 CHAMPIONS ONCOLOGY, INC.  
 [CSBR]

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

(Last) (First) (Middle)

3. Date of Earliest Transaction  
 (Month/Day/Year)  
 03/16/2015

Director  10% Owner  
 Officer (give title below)  Other (specify below)  
 President

C/O CHAMPIONS ONCOLOGY, INC., ONE UNIVERSITY PLACE, SUITE 307

(Street)

4. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check Applicable Line)  
 Form filed by One Reporting Person  
 Form filed by More than One Reporting Person

HACKENSACK, NJ 07601

(City) (State) (Zip)

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

| 1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transaction Code (Instr. 8) | 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Ownership (Instr. 4) |
|---------------------------------|--------------------------------------|--|--------------------------------|---|---|--|-----------------------------------|
|                                 |                                      |  |                                | (A) or (D)  | Price   |  |                                   |
|                                 |                                      |  |                                | Code  | V   | Amount   |                                   |

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

SEC 1474 (9-02)

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

Edgar Filing: CHAMPIONS ONCOLOGY, INC. - Form 4

| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transaction Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) | 6. Date Exercisable and Expiration Date (Month/Day/Year) |     | 7. Title and Amount of Underlying Securities (Instr. 3 and 4) |                 |              |                      |
|--|--|--------------------------------------|--|--------------------------------|---|--|-----|---|-----------------|--------------|----------------------|
|  |  |                                      |  | Code                           | V   | (A)  | (D) | Date Exercisable  | Expiration Date | Title        | Amount Number Shares |
| Option to purchase Common Stock            | \$ 0.41  | 03/16/2015                           |  | A                              |   | 2,190,958  |     | <u>(1)</u>  | 10/25/2020      | Common Stock | 2,190,958            |
| Option to purchase Common Stock            | \$ 0.41  | 03/16/2015                           |  | A                              |   | 2,190,959  |     | <u>(2)</u>  | 10/25/2020      | Common Stock | 2,190,959            |
| Option to purchase Common Stock            | \$ 0.41  | 03/16/2015                           |  | A                              |   | 1,347,977  |     | <u>(3)</u>  | 11/05/2013      | Common Stock | 1,347,977            |
| Option to purchase Common Stock            | \$ 0.41  | 03/16/2015                           |  | A                              |   | 1,347,977  |     | <u>(4)</u>  | 11/05/2013      | Common Stock | 1,347,977            |
| Option to purchase Common Stock            | \$ 0.41  | 03/16/2015                           |  | A                              |   | 193,210  |     | <u>(5)</u>  | 11/05/2013      | Common Stock | 193,210              |
| Option to purchase Common Stock            | \$ 0.41  | 03/16/2015                           |  | A                              |   | 1,084,298  |     | <u>(6)</u>  | 03/16/2015      | Common Stock | 1,155,000            |

## Reporting Owners

| Reporting Owner Name / Address   | Relationships |           |           |       |
|--|---------------|-----------|-----------|-------|
|  | Director      | 10% Owner | Officer   | Other |
| Morris Ronnie<br>C/O CHAMPIONS ONCOLOGY, INC.<br>ONE UNIVERSITY PLACE, SUITE 307<br>HACKENSACK, NJ 07601 | X             |           | President |       |

## Signatures

/s/ Ronnie Morris  
03/23/2015

\_\_Signature of  
Reporting Person

Date

## Explanation of Responses:

- \* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Fully vested upon grant.
- (2) Fully vested upon grant.
- (3) Vested as to 561,655 shares on grant; remainder vests quarterly over period ending on November 4, 2016, with the next vesting to occur on May 5, 2015.
- (4) Vesting to occur upon completion of performance criteria that have not been set.
- (5) Fully vested upon grant.
- (6) Vested as to 271,075 shares on grant; remainder vests quarterly over period ending on November 4, 2015, with the next vesting to occur on May 5, 2015.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.